Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...
Oculis’ neuroprotective candidate privosegtor receives US FDA breakthrough therapy designation to treat optic neuritis: Zug, Switzerland Thursday, January 8, 2026, 17:00 Hrs [IS ...
Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential ...
Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing ...
In the year after surgery for primary congenital glaucoma, gas-permeable contact lenses led to significantly better visual ...
Accuity, an AI-driven clinical intelligence and revenue integrity partner for leading health systems, today announced its ...
Some of the most amazing nursing homes I’ve seen in my career are of the mom-and-pop variety. But the number of these in the U.S. has dramatically ...
Sanofi may rebid for Ocular Therapeutix, Inc. to boost retinal therapeutics ahead of Dupixent patent expiry. Click for more ...
Last year, it emerged that Health New Zealand used an Excel spreadsheet as its "primary data file" for managing and analysing ...
Investor's Business Daily on MSN
Acuity Stock, Fast-Growing Data Center Operator Headline 2026 Earnings Calendar
Acuity stock is near highs and headlines the latest earnings calendar along with data center operator Applied Digital.
Holding announced that its neuroprotective candidate Privosegtor was granted breakthrough therapy designation by the U.S. Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback